Baumann Oliver Rolf
Known title: DirectorCIK: 0002129436
Baumann Oliver Rolf's purchase track record
Baumann Oliver Rolf has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2026 | VRXA | $75K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VRXA | ▲ Buy | Open Market | 50,000 | $75K | 8/27/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Veraxa Biotech Advances Oncology Pipeline with Xlife First‑Half Progress
Xlife Sciences released first‑half results showing progress on Veraxa’s BiTAC platform, expanding the company’s oncology pipeline. The update signals that Veraxa’s public‑market story is moving into its next development phase. These developments add depth to the company’s pipeline, which could support future product launches.
Veraxa Biotech Advances Oncology Pipeline with Xlife First‑Half Progress. Xlife Sciences released first‑half results showing progress on Veraxa’s BiTAC platform, expanding the company’s oncology pipeline. The update signals that Veraxa’s public‑market story is moving into its next development phase. These developments add depth to the company’s pipeline, which could support future product launches.